Luke Evnin

Luke Evnin, Ph.D.

Luke Evnin, Ph.D., co-founded MPM with Ansbert Gadicke in 1997 and opened the San Francisco office in 1999. The MPM team they have led has been the inspiration and driving force behind building companies such as Biomarin (BMRN), CoStim Pharmaceuticals (acquired by Novartis:NVS) , Epizyme (EPZM), Idenix (acquired by Merck:MRK), Pacira (PCRX), Pharmasset (acquired by Gilead:GILD) and Radius (RDUS). MPM believes that these companies are among the biggest successes in biotech history – companies that ultimately resulted in helping thousands of patients live longer and with vastly improved lives. Luke was the lead investor and has served on the boards of several of MPM’s most successful investments including CoStim Pharmaceuticals, Idun Pharmaceuticals, and Pacira. 

Prior to co-founding MPM, Luke honed his skills as a venture capitalist beginning in 1990 at Accel Partners where he focused on emerging healthcare companies. Luke’s passion for drug discovery began in college where he received his A.B. in Molecular Biology from Princeton University. He advanced his technical training and launched his interest in curing disease with his doctoral study in the Department of Biochemistry at the University of California-San Francisco. Luke’s passion for discovering and pushing forward groundbreaking drug discovery companies inspires his work and that of his team. 

Luke has devoted significant efforts since 2000 to working with the Scleroderma Research Foundation, serving as Chairman since 2002. Luke also devotes energy to the External Advisory Board at the Lewis-Sigler Institute for Quantitative Genomics at Princeton, serves on the External Advisory Boards for QB3 at UCSF, the Masters in Translational Medicine program at UCSF, and the Boston University Scleroderma CORT.


Briggs W. Morrison, MD

Briggs W. Morrison, M.D. 

Briggs W. Morrison, M.D., joined MPM in 2015. Briggs is CEO of Syndax Pharmaceuticals, Inc., an MPM portfolio company. Prior to joining Syndax and MPM, Briggs served as Chief Medical Officer and Executive VP for “Global Medicines Development” at AstraZeneca (ADR). 

Briggs’ career includes distinguished roles at AstraZeneca, Pfizer (PFE) and Merck (MRK). At AstraZeneca, he was head of global medicines development, where he oversaw all clinical development functions and late- stage clinical development projects. As Head of Clinical Development at Pfizer, he oversaw Phase I-III development and operations for all therapeutic areas before being appointed the head of Development, Medical Affairs, Safety and Regulatory Affairs for all Pfizer human health businesses. While serving as head of Oncology Development at Merck, Briggs oversaw the development and approval of vorinostat (Zolinza ®) for the treatment of cutaneous T-cell lymphoma. Briggs formerly served as Chairman of the Board of Transcelerate, an industry-funded company charged with improving aspects of clinical trials. 

Briggs received his BS (Biology) degree from Georgetown University and his MD degree from the University of Connecticut, and completed a post-doctoral research fellowship in the Department of Genetics at Harvard Medical School and additional post-doctoral work at the Dana-Farber Cancer Institute. Briggs trained in Internal Medicine at the Massachusetts General Hospital and in Medical Oncology at the Dana-Farber Cancer Institute.


Alon Lazarus, Ph.D.

Alon Lazarus is a Biotech Investment Manager for Arkin Holdings' Pharma Division. He is a member of the Board of several of its pharmaceutical companies, including Quiet Therapeutics, Keros Therapeutics and Lutris Pharma. Prior to joining Arkin, Alon Lazarus worked for the Healthcare Business Development Department of Yissum - the Research & Development arm of the Hebrew University and as an analyst for the University's Integra Holdings. Dr. Lazarus holds a Ph.D in Molecular Biology and an MBA - both from the Hebrew University of Jerusalem in Israel.


Oncorus logo placeholder for Cameron Wheeler

Cameron Wheeler, Ph.D.

Cameron is a Principal on the Private Transactions team at Deerfield. Cameron joined Deerfield in 2014 and focuses on therapeutics companies. Prior to joining Deerfield, Cameron was at Eleven Biotherapeutics for more than five years, where he was responsible for corporate development and commercial strategy. He was instrumental in the founding, building, and the eventual public offering of Eleven Biotherapeutics. Prior to Eleven, Cameron was at Third Rock Ventures, a Boston-based venture capital firm focused on launching and building life science companies. While at Third Rock, Cameron gained business development and operating experience as a member of the founding team of Constellation Pharmaceuticals. Cameron holds a Ph.D. and S.M. in Biological Engineering and an S.B. in Mechanical Engineering from Massachusetts Institute of Technology.